
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is poised for significant growth thanks to its innovative Deep TMS technology, which has shown comparable remission and response rates to traditional protocols while significantly reducing the number of clinic visits required. In addition, the recent FDA approval of Neurolief's ProlivRx device for at-home use and the company's strategic investment in Neurolief further enhance its potential. Furthermore, BrainsWay's virtual analyst and investor day demonstrated strong tailwinds for the company, including ongoing transformation of neuropsychiatry and the quantum leap of its Deep TMS360 technology.
Bears say
BrainsWay is an innovative company with a solid financial performance, evidenced by its 2025 top-line revenue totaling $52.2 million and full-year diluted earnings of $0.18 per share. However, we have a negative outlook on the stock due to the recent reduction in the ratio of American Depositary Shares (ADSs) to ordinary shares, the need for continued investments to drive revenue growth, and the limited coverage of its accelerated Deep TMS protocol for the treatment of MDD. Additionally, the stock's performance may be impacted by the company's dependence on lease agreements for customer engagements and the potential for limited reimbursement from insurance providers.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares